Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (CRPC) and gastric cancer.
CAS Number:
[872514-65-3]
Target:
c-Met/HGFR
* VAT and and shipping costs not included. Errors and price changes excepted